...
机译:MA11.07肿瘤细胞中LAG-3和NY-ESO-1的表达是有前途的生物标志物,预测高级NSCLC中PD-1封闭的耐用临床益处
Kangwon National University Hospital;
Seoul National University Bundang Hospital;
Seoul National University Bundang Hospital;
Seoul National University Bundang Hospital;
Department of Internal Medicine Seoul National University Hospital;
Department of Internal Medicine Seoul National University Hospital;
Seoul National University Hospital;
Pathology Seoul National University Bundang Hospital;
Department of Internal Medicine Seoul National University Hospital;
Seoul National University Hospital;
Seoul National University Bundang Hospital;
机译:MA11.07肿瘤细胞中LAG-3和NY-ESO-1的表达是有前途的生物标志物,预测高级NSCLC中PD-1封闭的耐用临床益处
机译:肿瘤LAG-3和NY-ESO-1表达预测晚期非小细胞肺癌中免疫检查点抑制剂的耐用临床益处
机译:PD-1阻断治疗晚期实体肿瘤患者循环肿瘤细胞PD-L1表达的动态变化
机译:单细胞水平晚期NSCLC患者EGFR激活突变的细胞内异质性
机译:T细胞功能和PD-1检查点延迟肿瘤进展
机译:在人类卵巢癌中肿瘤浸润性NY-ESO-1特异性CD8 + T细胞受到LAG-3和PD-1的负调控
机译:肿瘤LAG-3和NY-ESO-1表达预测晚期非小细胞肺癌免疫检查点抑制剂的耐用临床益处